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Abstract 
Background: Data regarding the outcome of patients with ventricular tachyarrhythmias 
related to arterial hypertension (AHT) and smoking is limited. The study sought to assess the 
prognostic impact of AHT and smoking on survival in patients presenting with ventricular 
tachyarrhythmias.  
Methods: All consecutive patients surviving ventricular tachycardia (VT) and ventricular 
fibrillation (VF) upon admission to the University Medical Center Mannheim (UMM), 
Germany from 2002 to 2016 were included and stratified according to AHT and smoking by 
propensity score matching. The primary prognostic endpoint was all-cause mortality at 30 
months.   
Results: A total of 988 AHT-matched patients (494 each, with and without AHT) and a total 
of 872 smoking-matched patients (436 each, with and without smoking) were included. The 
rates of VT and VF were similar in both groups (VT: AHT 60% vs. no AHT 60%; smokers 
61% vs. non-smokers 62%; VF: AHT 35% vs. no AHT 38%; smokers 39% vs. non-smokers 
38%). Neither AHT nor smoking were associated with the primary endpoint of long-term all-
cause mortality at 30 months (long-term mortality rates: AHT/no AHT, 26% vs. 28%; log-
rank p=0.525; smoking/non-smoking, 22% vs. 25%; log-rank p = 0.683).  
Conclusions: Paradoxically, neither AHT nor smoking were associated with differences of 
long-term all-cause mortality in patients presenting with ventricular tachyarrhythmias. 
Key words: ventricular tachyarrhythmias, arterial hypertension, smoking, long-term 
all-cause mortality 
Introduction 
Sudden cardiac death (SCD) related to ventricular tachyarrhythmias accounts for 15–20% 
of all deaths in the Western world and remains associated with poor clinical outcomes [1]. 
Therefore, it is important to stratify high-risk patients presenting with ventricular 
tachyarrhythmias according to their individual risk for future outcomes.  
Arterial hypertension (AHT) and nicotine, a major component of cigarettes inhaled 
during smoking, are common cardiovascular risk factors for coronary artery disease (CAD) 
and heart failure (HF) [2–4]. Patients suffering from CAD and HF are at risk of developing 
life-threatening ventricular tachyarrhythmias [2, 5]. Ventricular tachyarrhythmias are also 
associated with left ventricular hypertrophy (LVH) due to long-standing AHT [4, 6]. The 
pathogenesis of ventricular tachyarrhythmias in patients suffering from AHT is multifactorial, 
including hemodynamic and electrophysiological changes such as QT-prolongation [2, 7]. 
Likewise, it could be speculated if an antihypertensive medication including thiazide diuretics 
might induce electrolyte shifts such as hypokalemia alleviating the onset of ventricular 
tachyarrhythmias [2, 8]. The influence of AHT on the development of ventricular 
tachyarrhythmias is well described, whereas the prognostic impact of AHT in these high-risk 
patients is unclear.  
Smoking of cigarettes is the most important modifiable risk factor for CAD [9]. The 
effect of smoking on progression of CAD is well established [3]. Nicotine by itself might 
induce acute vascular events due to induction of hypercoagulable states, induction of 
endothelial dysfunction, catecholamine release, and several toxic effects of increased carbon 
monoxide blood levels [10]. The role of smoking itself on ventricular tachyarrhythmias is still 
debated [2, 3]. Nicotine has been proven to induce arrhythmogenesis in animals, whereas 
these findings have not yet been approved in humans [3]. However, there is no data available 
as to whether smoking has an impact on long-term mortality in patients presenting with 
ventricular tachyarrhythmias [3].  
Therefore, the present study evaluates the prognostic impact of AHT and smoking on 
long-term all-cause mortality in patients presenting with ventricular tachyarrhythmias upon 
admission. 
 
Methods 
Study patients, design and data collection 
The present study retrospectively included all consecutive patients with ventricular 
tachyarrhythmias from 2002 until 2016 at one institution. All relevant clinical data related to 
the index event was documented using patient files, daily records, documentation from 
diagnostic examinations and laboratory values, electrocardiograms (ECG), device recordings, 
and all further information derived from the electronic hospital information system.   
Ventricular tachyarrhythmias are comprised of ventricular tachycardia (VT) and 
ventricular fibrillation (VF), as defined by current international guidelines [11]. Sustained VT 
herein, was defined by VT with a duration of more than 30 s or causing hemodynamic 
collapse within 30 s. Non-sustained VTs were defined as less than 30 s. VTs were comprised 
of wide QRS complexes (≥ 120 ms) at a rate greater than 100 bpm [11]. Ventricular 
tachyarrhythmias were documented by 12-lead ECG, ECG tele-monitoring and implantable 
cardioverter-defibrillators (ICD). In cases of unstable course or during cardiopulmonary 
resuscitation (CPR) documentation was performed by external defibrillator monitoring. 
Documented VF was treated by external defibrillation and in cases of prolonged instability 
with additional intravenous anti-arrhythmic drugs during cardiopulmonary resuscitation 
(CPR). Further documented data contained baseline characteristics, prior medical history, 
prior medical treatment, length of index stay, detailed findings of laboratory values at 
baseline, data derived from all non-invasive or invasive cardiac diagnostics and device 
therapies. These included coronary angiography, electrophysiological examination, prior or 
newly implanted ICDs, pacemakers or cardiac contractility modulators (CCM), which had 
already been implanted at index or at follow-up. Imaging modalities comprised 
echocardiography or cardiac magnetic resonance imaging (cMRI). The overall presence of an 
activated ICD summarizes the total sum of all patients with either a prior implanted ICD 
before admission, those undergoing new ICD implantation at index stay, as well as those with 
ICD implantation at the complete follow-up period after index hospitalization, referring to 
sole ICD, subcutaneous-ICD (s-ICD) and cardiac resynchronization therapy with defibrillator 
function (CRT-D). Pharmacological treatment was documented according to the discharge 
medication of patients surviving index hospitalization. Rates of overall ICDs and of 
pharmacological therapies refer to the number of surviving patients being discharged from 
index hospitalization.  
The documentation period lasted from the index event until 2016. Documentation of all 
medical data was performed by independent cardiologists at the patients’ individual period of 
hospitalization and were blinded to the final data analyses.  
The present study is derived from an analysis of the “Registry of Malignant Arrhythmias 
and Sudden Cardiac Death-Influence of Diagnostics and Interventions (RACE-IT)” and 
represents a single-center registry including retrospectively consecutive patients presenting 
with ventricular tachyarrhythmias and SCD being acutely admitted to the University Medical 
Center Mannheim (UMM), Germany (clinicaltrials.gov identifier: NCT02982473) from 2002 
until 2016. The registry was carried out according to the principles of the declaration of 
Helsinki and was approved by the medical ethics committee II of the Faculty of Medicine 
Mannheim, University of Heidelberg, Germany.  
The medical center covers a general emergency department (ED) for emergency 
admission of traumatic, surgical, neurological and cardiovascular conditions. Interdisciplinary 
consultation is an inbuilt feature of this 24/7 service, and is connected to a stroke unit, four 
intensive care units (ICU) with extracorporeal life support and a chest pain unit (CPU) to 
alleviate rapid triage of patients. The cardiology department itself includes 24 h 
catheterization and electrophysiologic laboratories, a hybrid operating room and telemetry 
units. 
 
Definition of study groups, inclusion and exclusion criteria  
For the present analysis risk stratification was performed according to AHT and 
smoking. AHT was defined by international guidelines as systolic blood pressure levels ≥ 140 
mmHg and/or diastolic blood pressure levels ≥ 90 mmHg, at which the benefits of treatment 
overweighed the risks of treatment, i.e. lifestyle modification or antihypertensive drugs [12]. 
Smoking was defined by daily nicotine use [13]. Overall exclusion criteria comprised patients 
with early cardiac death. Early cardiac death was defined as cardiac death occurring < 24 h 
after onset of ventricular tachyarrhythmias or an assumed unstable cardiac condition on index 
admission [11]. No further exclusion criteria were present. 
Each patient was counted only once for inclusion when presenting with the first episode 
of ventricular tachyarrhythmias.  
 
Study endpoints 
The primary prognostic endpoint was all-cause mortality at long-term follow-up of 30 
months. Overall follow-up lasted until 2016. All-cause mortality was documented using our 
electronic hospital information system and by directly contacting state resident registration 
offices (“bureau of mortality statistics”) across Germany. Identification of patients was 
verified by place of name, surname, day of birth and registered living address. Lost to follow-
up rate was 1.7% (n = 48) regarding survival until the end of the follow-up period. 
 
Statistical methods 
Quantitative data are presented as mean ± standard error of mean (SEM), median and 
interquartile range (IQR), and ranges depending on the distribution of the data and were 
compared using the Student t test for normally distributed data or the Mann-Whitney U test 
for nonparametric data. Deviations from a Gaussian distribution were tested by the 
Kolmogorov-Smirnov test. The Spearman rank correlation for nonparametric data was used to 
test univariate correlations. Qualitative data are presented as absolute and relative frequencies 
and were compared using the χ2 test or the Fisher exact test, as appropriate.  
Uni-variable stratification was performed using the Kaplan-Meier method with 
comparisons between groups using uni-variable hazard ratios (HR) given together with 95% 
confidence intervals applied in the propensity-matched cohorts.  
Follow-up periods for evaluation of all-cause mortality was in accordance with the 
median survival of diseased patients to guarantee complete survival of at least 50% of 
patients. Patients not meeting long-term follow-up were censored.  
The result of a statistical test was considered significant for p < 0.05, p values ≤ 0.01 
were defined as a statistical trend. SAS, release 9.4 (SAS Institute Inc., Cary, NC, USA) and 
SPSS (Version 25, IBM Armonk, New York, USA) were used for statistics.  
 
Propensity score matching 
Propensity matching was applied in advance (see study flow chart) and all statistical 
calculations as outlined above were performed in the propensity matched cohort afterwards.  
In randomized controlled trials (RCT) patients with or without a specific treatment would 
have a 50% chance of  being treated and balanced measured and unmeasured baseline 
characteristics would be expected. However, patients cannot be randomized in real-life 
according to AHT and smoke. An observational study usually recruits consecutive real-life 
patients without randomization resulting in varying chances between 0% and 100% to receive 
imbalances in baseline characteristics and treatments. Therefore, differences inoutcomes of 
specific groups might be explained by heterogeneous distribution of baseline characteristics 
and applied therapies. To further reduce this selection bias, a 1:1 propensity-scores were used 
for AHT vs. no AHT and smokers vs. non-smokers, to assemble matched cohorts, in which 
patients were well-balanced regarding all measured baseline characteristics. 1:1 propensity 
score matching was performed and included the entire study cohort [14, 15]. 
Propensity scores were created according to the presence of the following independent 
variables: age, gender, diabetes, chronic kidney disease (CKD) (glomerular filtration rate < 60 
mL/min/1.73 m2), coronary artery disease (CAD), left ventricular dysfunction, CPR, acute 
myocardial infarction (AMI), cardiogenic shock, presence of an ICD and index ventricular 
tachyarrhythmias (VT vs. VF).  
Based on propensity score values counted by logistic regression, for each AHT a non-
AHT patient and for each smoking patient, a non-smoking patient with a similar propensity 
score value was found (accepted difference of propensity score value < 5%). 
 
Results 
Study population 
Propensity-matched cohorts of consecutive patients presenting with ventricular 
tachyarrhythmias on admission at our institution consisted of a total of 988 patients in AHT 
and 872 patients in smoking cohorts.  
In the AHT cohort (494 patients in each group), the rate of VT and VF was similar in 
both groups (VT: AHT 60% vs. no AHT 60%; VF: AHT 40% vs. no AHT 40%) (Table 1). 
No further differences were observed for prognosis-relevant factors at index including CKD, 
CAD, AMI, cardiogenic shock, cardiomyopathy as well as discharge medication with beta-
blockers, angiotensin-converting enzyme inhibitors (ACEI) and aldosterone antagonists in 
between AHT and no AHT patients (Table 1).  
In the smoking cohort (436 patients in each group), the rate of VT and VF was similar in 
both groups (VT: smokers 61% vs. non-smokers 62%; VF: smokers 39% vs. non-smokers 
38%) (Table 2). Despite matching for prognosis-relevant factors at index including CKD, 
CAD, AMI, cardiogenic shock, cardiomyopathies and atrial fibrillation, smokers were still 
more likely to have a prior history of AHT, hyperlipidemia, cardiac family history and ACEI 
at discharge (Table 2).  
The AHT cohort and the smoker’s cohort were well matched for left ventricular function, 
cardiac therapies at index including CPR, diagnostics including coronary angiography and 
CAD status and device therapies (Tables 1, 2). Smokers underwent coronary angiography 
more often and revealed a higher rate of overall CAD.  
 
All-cause mortality and survival data 
Paradoxically, at long-term follow-up high-risk AHT patients presenting with ventricular 
tachyarrhythmias were not associated with the primary endpoint of long-term all-cause 
mortality at 30 months (IQR 96 days – 5.5 years) compared to no AHT patients (mortality 
rates: AHT, 26% vs. no AHT: 28%; log-rank p = 0.525) (Fig. 2).  
Arterial hypertension was not associated with the primary endpoint of long-term all-cause 
mortality in CRT (HR 0.511 [0.132–1.976]; p = 0.330) and no-CRT patients (HR 0.942 
[0.736–1.205]; p = 0.942) as well as in patients with left ventricular ejection fraction (LVEF) 
> 35% and LVEF < 35% (LVEF > 35%, log-rank p = 0.497; LVEF < 35%, log-rank p = 
0.753) (data not shown). 
Accordingly, smokers presenting with ventricular tachyarrhythmias on admission were 
not associated with the primary endpoint of all-cause mortality at 30 months compared to 
non-smokers (mortality rate smokers: 22% vs. non-smokers: 25%; log-rank p = 0.683) (Fig. 
3). Even in patients with LVEF > 35% smoking was not associated with any mortality 
difference (LVEF > 35%, log-rank p = 0.649; LVEF < 35%, log-rank p = 0.239) (data not 
shown). 
 
Discussion 
The present study evaluates the prognostic impact of AHT and smoking on long-term all-
cause mortality in high-risk patients presenting consecutively with ventricular 
tachyarrhythmias on admission. Paradoxically, this well-matched analysis suggests that 
neither AHT nor smoking were associated with increased secondary long-term all-cause 
mortality at 30 months in patients presenting consecutively with ventricular tachyarrhythmias 
straight from the admission scenario. 
Previous studies showed that LVH due to AHT is a risk factor for ventricular 
tachyarrhythmias [16]. Data from the Framingham cohort demonstrated in 1985, that AHT 
may increase the risk of sustained or non-sustained VT in the presence of LVH [17]. 
Depending on the grade of LVH, the authors showed an increasing risk of cardiovascular and 
death of any cause. However, this study did not report on a long-term follow up of patients 
presenting on admission with ventricular tachyarrhythmias according to the presence of AHT. 
The present study did not prove any prognostic impact of AHT on long-term prognosis in 
patients presenting with ventricular tachyarrhythmias. Notably, no prognostic impact of AHT 
was additionally observed in patients with or without CRT devices. 
McLenachan et al. [18] compared patients with and without LVH and AHT assessed by 
12-lead ECG (each n = 50) including matching for age, sex, smoking and blood-pressure 
levels. It was demonstrated that AHT/LVH patients had a significant higher rate of ventricular 
tachyarrhythmias and SCD compared to patients without LVH [18]. Furthermore, effective 
control of blood pressure was shown to prevent ventricular tachyarrhythmias and SCD [16]. 
Especially, antihypertensive drugs, such as thiazide diuretics, were associated with ventricular 
tachyarrhythmias due to electrolyte shifts. Although, the exact mechanism is not fully 
understood, hypokalemia might play an important role [19]. In the double-blind and 
randomized HOPE-study the ACEI ramipril was associated with a reduced rate of death, 
myocardial infarction, stroke and cardiac arrest compared to placebo [20]. Since their market 
approval in the early 1980s, ACEI became the international gold standard in the therapy of 
AHT. ACEI are known to attenuate adverse structural myocardial remodeling and progression 
of LVH [21–23]. Data from Framingham and MCLenachan were collected until 1985/1987, 
whereas data about ACEI treatment were not reported sufficiently. It might be speculated as 
to whether the lack of prognostic impact of AHT itself may be attributed to modern therapies 
including ACEI within 2002 and 2016. In this study 26% of AHT patients had been already 
treated with ACEI.  
A majority of patients included in the present study suffered from systolic heart failure 
(LVEF < 55%) in almost two thirds of cases. Heart failure, especially in advanced stages 
(LVEF < 35%) is accompanied by progressive AHT in terms of low-output failure [24]. This 
might additionally support the hypothesis of risk-factor paradox in patients presenting with 
ventricular tachyarrhythmias related to AHT. Here, the implantation of CRT-devices 
represents an established treatment option in patients with wide QRS complexes and LVEF < 
35%, [25, 26] and aims to improve left ventricular dysfunction by an effective biventricular 
stimulation rate of > 98%, which in turn, may increase systolic blood pressure. However, 
there are known predictors of ineffective CRT response, such as permanent atrial fibrillation, 
massively dilated left ventricles, severe mitral regurgitation, and large ischemic anteroseptal 
or posterior scars of the left ventricle [26]. In order to test for potential bias, the present study 
demonstrates that AHT had no effect on prognosis and neither in CRT, non-CRT and LVEF < 
35% patients. However, the outlined circumstances might additionally support the hypothesis 
of the entitled risk-factor paradox in patients presenting with ventricular tachyarrhythmias 
related to AHT.  
The only and most modifiable cardiovascular risk factor represents the smoking of 
cigarettes, however smoking is still the leading preventable cause of death in the United 
States [3]. Smoking is directly associated with atherosclerosis, whereas its influence in 
patients with ventricular tachyarrhythmias is still unclear [3]. Several experimental studies 
investigated the toxicity of nicotine in animals and cell cultures. Mehta et al. [27] investigated 
the effect of intravenous application of nicotine in healthy dogs. In their dose-response study, 
increased rates of arrhythmias were observed at a dosage of 50 µg/kg (equivalent in humans 
of 2 smoked cigarettes), including supraventricular, atrioventricular junctional and ventricular 
arrhythmias [27]. An intravenous dosage of nicotine at 100 µg/kg was shown to induce fatal 
ventricular flutter and fibrillation. The arrhythmogenic side effect of nicotine was explained 
by increased carbon monoxide and oxidative stress [27]. Unfortunately, these experimental 
results are not directly comparable to humans, due to long-term use of smoking in humans [3, 
27].   
In a case-control study including 95 CAD patients undergoing bypass surgery smoking 
was an independent predictor of atrial fibrosis [28]. Goette et al. [28] demonstrated increased 
levels of collagen type III within an organo-typical atrial tissue culture model of smokers. 
This pro-fibrotic status (i.e. increase of extracellular matrix turnover and subsequent adverse 
structural myocardial remodeling) as a consequence of nicotine was also shown in an 
experimental study in dogs by Shan et al. [29], where a dose-dependent increase of atrial 
remodeling after intravenous administration of nicotine over 30 days was documented. Atrial 
tissue was preserved during open-heart surgery of the dogs and the fibrous tissue was finally 
quantified microscopically [3]. Furthermore, arrhythmogenesis might be related to tissue 
hypoxemia, oxidative stress and increased carbon monoxide by binding hemoglobin during 
smoking [30, 31].  
Plank et al. [32] investigated in a sub-study of the Multicenter Automatic Defibrillator 
Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT-trial) the risk of first 
and recurrent ventricular tachyarrhythmias in patients with mild heart failure and ICD therapy 
according to smoking [32]. The study compared 465 non-smokers, 780 past smokers and 197 
current smokers with ischemic and non-ischemic cardiomyopathy [32]. Current smokers with 
mild heart failure were shown to be associated with higher risk of ventricular 
tachyarrhythmias compared to past- and non-smokers [32]. The MADIT-II trial showed that 
the risk of ventricular tachyarrhythmias in patients with CAD-related heart failure is higher in 
current smokers compared to past- and non-smokers. They also showed that smokers had a 
significantly higher risk for inadequate ICD-shocks [33]). MADIT-II and MADIT-CRT were 
primary preventive studies, whereas the present study included patients who already survived 
an episode of ventricular tachyarrhythmias on admission. Unfortunately, sub-analyses of 
MADIT did not undergo propensity matching which questions the results due to cofounding 
of heterogeneous sub-groups regarding comorbidities.  
Data about the effect of nicotine and cardiac arrhythmia are limited in humans. 
Pharmacodynamics of nicotine is complex including the biphasic dose-response curve and 
additional development of nicotine tolerance. Therefore, more studies in humans are 
necessary to prove potential acute toxic and long-term prognostic effects of nicotine in 
patients presenting with ventricular tachyarrhythmias [3, 34–36]. Consistently, smoking does 
represent a risk factor for development of CAD and chronic obstructive pulmonary disease 
(COPD). Both diseases might promote ventricular tachyarrhythmias by themselves [37]. No 
evidence is yet available whether smoking may affect prognosis in the absence of CAD and 
COPD, even in high-risk patients with ventricular tachyarrhythmias.  
In conclusion, this study demonstrates a paradox that neither AHT nor smoking reveal 
any impact on long-term prognosis in terms of all-cause mortality in high-risk patients 
presenting with ventricular tachyarrhythmias on admission.  
 
Limitations of the study 
This observational and retrospective registry-based analysis reflects a realistic picture of 
consecutive health-care supply of high-risk patients presenting with ventricular 
tachyarrhythmias right upon hospital admission. Lost to follow-up rate regarding the 
evaluated endpoint of all-cause mortality was minimal. Additionally, heterogeneity within the 
study population was controlled by 1:1 propensity-matched analyses. The potential influence 
of optimal treatment of hypertensive patients as well as investigation of smoking cessation 
programmes being offered at the documented institution might still have influenced the 
present results to a minor extent. Despite retrospective propensity-score matching with similar 
rates of cardioprotective drugs in both AHT and no AHT patients and no differences after 
stratification into left ventricular dysfunction, a certain bias may still be present especially in 
hypotensive patients associated with progressive heart failure usually receiving minor dosages 
and numbers of cardioprotective drugs. Also, a CRT-treatment might improve the blood 
pressure and consecutive the survival in hypotensive patients. The prognostic impact of AHT 
and smoking in patients with ventricular tachyarrhythmias has to be re-evaluated in further 
studies. 
 
Conclusions 
Paradoxically, arterial hypertension and smoking were not associated with increased 
long-term all-cause mortality at 30 months in patients presenting with ventricular 
tachyarrhythmias on admission. 
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 Figure 1. Flow chart of study population. 
 
Figure 2. Long-term all-cause mortality of patients presenting with ventricular 
tachyarrhythmias stratified according to the presence and absence of arterial hypertension. 
 
Figure 3. Long-term all-cause mortality of patients presenting with ventricular 
tachyarrhythmias stratified according to the presence and absence of smoking. 
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 Table 1.  Characteristics of matched patients with or without arterial hypertension 
Characteristic 
Non-AHT 
(n=494; 50%) 
AHT 
(n=494; 50%) 
p value 
Gender, n (%)      
    Male 376 (76) 378 (77) 0.881 
Age, median (range) 65 (21-89) 65 (30-94) 0.396 
Ventricular tachyarrhythmias, n (%)      
 Ventricular tachycardia 296 (60) 298 (60) 
0.897 
 Ventricular fibrillation 198 (40) 196 (40) 
Cardiovascular risk factors, n (%)      
Diabetes mellitus 90 (18) 115 (23) 0.050 
Hyperlipidemia 74 (15) 211 (43) 0.001 
Smoking 140 (28) 160 (32) 0.166 
Cardiac family history 52 (11) 63 (13) 0.275 
Comorbidities at index stay, n (%)      
Acute myocardial infarction 161 (33) 145 (29) 0.271 
Cardiogenic shock 58 (12) 59 (12) 0.922 
Cardiopulmonary resuscitation 187 (38) 177 (36) 0.510 
Cardiomyopathy 78 (16) 60 (12) 0.099 
Valvular heart disease 44 (9) 42 (9) 0.821 
Atrial fibrillation 137 (28) 173 (35) 0.014 
Cardiac surgery 7 (1) 7 (1) 1.000 
Hyperkalemia 7 (1) 8 (2) 0.795 
Hypokalemia 28 (6) 34 (7) 0.431 
Stroke 15 (3) 19 (4) 0.485 
Clinically significant bleeding  18 (4) 16 (3) 0.727 
Anemia  24 (5) 31 (6) 0.331 
Septic shock 13 (3) 13 (3) 1.000 
Chronic kidney disease 217 (44) 219 (44) 0.898 
Liver cirrhosis 7 (1) 4 (0.8) 0.363 
Coronary angiography, n (%)      
Coronary angiography, overall 337 (68) 368 (75) 0.029 
Coronary artery disease, n (%) 243 (72) 254 (69) 0.130 
No evidence of CAD 94 (28) 114 (31) 0.163 
1-vessel 78 (23) 100 (27) 0.069 
2-vessel 88 (26) 70 (19) 0.118 
3-vessel 77 (23) 84 (23) 0.547 
Presence of CABG 37 (11) 44 (12) 0.684 
Presence of CTO 71 (21) 60 (16) 0.085 
PCI, n (%) 157 (47) 138 (38) 0.015 
Left ventricular function, n (%)      
LVEF >55% 143 (29) 150 (30) 
0.786 LVEF 54-35% 176 (36) 162 (33) 
LVEF <35% 175 (35) 182 (37) 
Patients at discharge, n (%) 426 (86) 442 (89) 0.119 
Overall ICDs 131 (31) 132 (30) 0.911 
Medication at discharge, n (%)      
Beta-blocker 358 (84) 379 (86) 0.482 
ACE inhibitor 290 (68) 314 (71) 0.342 
Alosterone antagonist 48 (11) 58 (13) 0.404 
Hospitalization time, days, (median (IQR))      
Total hospitalization time 13 (8-22) 14 (8-23) 0.991 
ICU time 4 (0-8) 3 (0-8) 0.278 
Follow-up time, days  
(mean; median (range)) 
1719;1539 
(3-5095) 
1809;1595 
(3-5106) 
0.331 
All-cause mortality at 30 months, n (%)      
At index 68 (14) 52 (11) 0.119 
At follow up  68 (14) 76 (15) 0.471 
Overall 136 (28) 128 (26) 0.377 
AHT, arterial hypertension; AMI, acute myocardial infarction; ICD, implantable cardioverter-defibrillator; VF, 
ventricular fibrillation; VT, ventricular tachycardia. CABG; coronary artery bypass grafting; CAD, coronary 
artery disease; CTO, coronary chronic total occlusion; LVEF, left ventricular ejection function; ICU, intensive 
care unit; IQR, interquartile range; PCI, percutaneous coronary intervention. 
 Table 2.  Baseline characteristics according to smoking status. 
Characteristic 
Non-smoking 
(n=436;50%) 
Smoking 
(n=436;50%) 
p 
value 
Gender, n (%)      
   Male 362 (83) 365 (84) 0.785 
Age, median (range) 65 (16-92) 63 (21-88) 0.001 
Ventricular tachyarrhythmias, n (%)      
Ventricular tachycardia 269 (62) 266 (61) 
0.835 
Ventricular fibrillation 167 (38) 170 (39) 
Cardiovascular risk factors, n (%)      
Arterial hypertension 252 (58) 293 (67) 0.004 
Diabetes mellitus 113 (26) 110 (25) 0.816 
Hyperlipidemia 135 (31) 180 (41) 0.002 
Cardiac family history 33 (8) 85 (20) 0.001 
Comorbidities at index, n (%)      
Acute myocardial infarction 132 (30) 155 (36) 0.097 
Cardiogenic shock 39 (9) 56 (13) 0.065 
Cardiomyopathy 47 (11) 36 (8) 0.204 
Cardiopulmonary resuscitation 156 (36) 156 (36) 1.000 
Valvular heart disease 30 (7) 26 (6) 0.581 
Atrial fibrillation 120 (28) 123 (28) 0.821 
Cardiac surgery 4 (0.9) 15 (3) 0.011 
Hyperkalemia 3 (0.7) 6 (1) 0.315 
Hypokalemia 31 (7) 16 (4) 0.024 
Stroke 8 (2) 19 (4) 0.032 
Clinically significant bleeding 6 (1) 15 (3) 0.047 
Anemia 19 (4) 21 (5) 0.746 
Septic shock 5 (1) 13 (3) 0.057 
Chronic kidney disease 175 (40) 173 (40) 0.890 
Liver cirrhosis 3 (0.7) 6 (1) 0.315 
Coronary angiography, n (%)      
Coronary angiography, overall 297 (68) 328 (75) 0.020 
Coronary artery disease, n (%) 234 (54) 263 (60) 0.047 
No evidence of CAD 63 (21) 65 (20) 0.837 
1-vessel 73 (25) 97 (30) 0.040 
2-vessel 81 (27) 71 (22) 0.797 
3-vessel 80 (27) 95 (29) 0.205 
Presence of CABG 45 (15) 44 (13) 0.535 
Presence of CTO 69 (23) 68 (21) 0.450 
PCI, n (%) 123 (41) 157 (48) 0.105 
Left ventricular function, n (%)      
LVEF >55% 126 (29) 125 (29) 
0.679 LVEF 54-35% 153 (35) 152 (35) 
LVEF <35% 157 (36) 159 (37) 
Patients at discharge, n (%) 399 (91) 389 (89) 0.181 
Overall ICDs 115 (29) 124 (32) 0.467 
Medication at discharge, n (%)      
Beta-blocker 338 (85) 341 (88) 0.231 
ACE inhibitor 257 (64) 286 (74) 0.006 
Aldosterone antagonist 32 (8) 47 (12) 0.058 
Hospitalization time, days, (median (IQR))      
Total hospitalization time 12 (4-23) 13 (8-23) 0.261 
ICU time 3 (0-8) 3 (0-8) 0.383 
Follow-up time, days  
(mean; median (range)) 
1954;1930 
(3-5095) 
1693;1527 
(3-5089) 
0.006 
All-cause mortality at 30 months, n (%)      
At index 37 (9) 47 (11) 0.191 
At follow up  71 (16) 51 (12) 0.051 
Overall 108 (25) 98 (22) 0.425 
AMI, acute myocardial infarction; ICD, implantable cardioverter-defibrillator; VF, ventricular fibrillation; 
VT, ventricular tachycardia. CABG; coronary artery bypass grafting; CAD, coronary artery disease; 
CTO, coronary chronic total occlusion; LVEF, left ventricular ejection function; ICU, intensive care 
unit; IQR, interquartile range; PCI, percutaneous coronary intervention. 
